{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-054003","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.022449+00:00","generated_at":"2026-06-01T03:16:54.200418+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aldeyra advances new RASP modulators ADX-743, ADX-248, ADX-631; pediatric ADX-629 top-line results expected 2025","bullets":["ADX-629 advanced to pediatric cohort in Sjögren-Larsson Syndrome Phase 2; top-line results from ~5 patients expected 2025.","Novel RASP modulator ADX-743 entered IND-enabling studies for obesity; IND submission planned 2025.","ADX-248 selected over ADX-246 for Phase 1/2 in atopic dermatitis; Phase 1 to start H2 2024.","ADX-631 initiated preclinical testing in retinal disease; IND submission for dry AMD/geographic atrophy expected H1 2025.","Investor roundtable webcast June 20, 2024 at 8:00 am ET to discuss these pipeline updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-054003","json":"https://secwatch.observer/filing/0001213900-24-054003.json","markdown":"https://secwatch.observer/filing/0001213900-24-054003.md","text":"https://secwatch.observer/filing/0001213900-24-054003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024054003/0001213900-24-054003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024054003/ea0208142-8k_aldeyra.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:16:54.200418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}